Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:ARQT

Arcutis Biotherapeutics Q3 2025 Earnings Report

Arcutis Biotherapeutics logo
$28.50 +0.83 (+3.00%)
Closing price 04:00 PM Eastern
Extended Trading
$28.55 +0.05 (+0.18%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Arcutis Biotherapeutics EPS Results

Actual EPS
$0.06
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Arcutis Biotherapeutics Revenue Results

Actual Revenue
$99.22 million
Expected Revenue
$86.69 million
Beat/Miss
Beat by +$12.53 million
YoY Revenue Growth
N/A

Arcutis Biotherapeutics Announcement Details

Quarter
Q3 2025
Date
10/28/2025
Time
Before Market Opens
Conference Call Date
Tuesday, October 28, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Arcutis Biotherapeutics' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q2 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Arcutis Biotherapeutics' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Arcutis Biotherapeutics' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Arcutis Biotherapeutics Earnings Headlines

Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic ...
July 8 at 1:23 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68974310-arcutis-biotherapeutics-inc-fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-mild-t-399.htm
Arcutis gets FDA review for Zoryve 0.05% label expansion
July 8 at 1:23 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4612312-arcutis-gets-fda-review-zoryve-005-label-expansion
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
July 8 at 1:00 AM  |  Profits Run (Ad)
Arcutis Biotherapeutics Inc
July 8 at 8:23 AM  |  cnn.comhttps://www.cnn.com/markets/stocks/ARQT
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
July 8 at 8:23 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months-1036306890
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
July 8 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324020/0/en/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months.html
See More Arcutis Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics (NASDAQ:ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies.

Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.

View Arcutis Biotherapeutics Profile
Earnings Tools